Preplanned per-protocol analysis excluding these patients showed stroke or death in three ( 3 % ) of 101 patients in the antiplatelet group versus one ( 1 % ) of 96 patients in the anticoagulant group ( OR 0346 , 95 % CI 0006-4390 ; p = 066 ) .